Welcome to our dedicated page for Mimedx Group SEC filings (Ticker: MDXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MiMedx Group, Inc. filings document the regulatory record for a Florida-incorporated regenerative biomaterials company serving wound care, burn and surgical healthcare markets. Form 8-K reports furnish quarterly and annual operating results, earnings materials, Regulation FD investor presentations and material events tied to business updates.
The company’s proxy materials cover board elections, executive compensation, equity-award valuation, pay-versus-performance data and shareholder voting matters. Recent current reports also document restructuring-related officer changes and temporary compensation reductions for named executive officers, linking governance disclosures to changes in the company’s cost structure.
MiMedx Group Director M. Kathleen Behrens received an annual restricted stock grant of 28,609 shares at $6.47 per share on June 18, 2025, increasing her total direct holdings to 212,771 shares.
Key details of the transaction:
- The grant is part of non-employee director compensation
- Transaction is exempt under Rule 16b-3
- Shares will vest at the earlier of 12 months or the next annual shareholder meeting
- Form 4 was filed by William F. Hulse as attorney-in-fact
This routine compensation grant demonstrates continued alignment between director and shareholder interests through equity-based compensation. The transaction represents approximately 13.4% increase in the director's direct holdings in the company.
MiMedx Group director James L. Bierman acquired 28,609 shares of common stock on June 18, 2025 at a price of $6.47 per share, bringing his total direct holdings to 212,771 shares.
The acquisition represents an annual restricted stock grant to non-employee directors and is exempt under Rule 16b-3. The awarded shares will vest upon the earlier of:
- 12 months from grant date
- The next annual meeting of shareholders
The Form 4 filing was signed by William F. Hulse as attorney-in-fact for Bierman on June 23, 2025. This transaction demonstrates continued alignment of director interests with shareholders through equity-based compensation.
MiMedx Group Director William A. Hawkins acquired 28,609 shares of common stock on June 18, 2025, at a price of $6.47 per share. This transaction represents an annual restricted stock grant to non-employee directors and is exempt under Rule 16b-3.
Following the transaction, Hawkins now beneficially owns a total of 204,018 shares directly. The restricted stock grant will vest upon the earlier of 12 months or the next annual meeting of shareholders.
Key Transaction Details:
- Transaction Type: Acquisition (Form 4)
- Stock Type: Common Stock
- Transaction Value: Approximately $185,100
- Ownership Form: Direct
- Filing Date: June 28, 2025
MiMedx Group director Cato T. Laurencin acquired 28,609 shares of common stock on June 18, 2025 at a price of $6.47 per share, bringing their total direct holdings to 181,923 shares.
The transaction represents an annual restricted stock grant to non-employee directors and is exempt under Rule 16b-3. Key details about the grant:
- Vesting occurs at the earlier of 12 months or next annual shareholder meeting
- Transaction was filed as a Form 4 pursuant to Section 16(a) of Securities Exchange Act
- The acquisition was reported as a direct ownership transaction
This insider transaction indicates ongoing compensation practices for board members and alignment with shareholder interests through equity-based compensation.
MiMedx Group director Tiffany Olson received an annual restricted stock grant of 28,609 shares on June 18, 2025, at a price of $6.47 per share. Following this transaction, Olson's direct ownership increased to 57,597 shares.
Key details of the grant:
- Transaction was filed as an exempt grant under Rule 16b-3
- Vesting occurs at the earlier of 12 months or next annual shareholder meeting
- Grant is part of standard non-employee director compensation
- Transaction was executed through attorney-in-fact William F. Hulse
This Form 4 filing represents routine board compensation and indicates continued alignment between director and shareholder interests through equity-based compensation.
MiMedx Group director Dorothy E. Puhy received an annual restricted stock grant of 28,609 shares on June 18, 2025, at a price of $6.47 per share. Following this transaction, Puhy's direct ownership increased to 57,597 shares.
Key transaction details:
- Transaction type: Non-derivative securities acquisition
- Grant type: Annual restricted stock award to non-employee director
- Vesting terms: Earlier of 12 months or next annual shareholder meeting
- Transaction exempt under Rule 16b-3
This Form 4 filing, signed by William F. Hulse as attorney-in-fact, represents standard annual director compensation in the form of equity, demonstrating continued alignment between director and shareholder interests.
MiMedx Group, Inc. (NASDAQ: MDXG) filed an 8-K summarizing the voting results of its 2025 Annual Meeting held on 18 June 2025. Shareholder participation was strong with 126.6 million shares (≈85.7% of the shares entitled to vote) represented in person or by proxy.
Key outcomes:
- Board elections: All nine incumbent directors were re-elected. Support ranged from 90.5 million to 97.2 million votes for, versus 4.5-10.3 million against. Broker non-votes totaled 24.7 million.
- Say-on-Pay (advisory): 94.8 million votes for, 6.9 million against, 0.2 million abstentions—about 93% approval.
- Auditor ratification: Deloitte & Touche LLP was confirmed with 123.7 million votes for and less than 1.0 million against (≈97% support).
- 2016 Equity & Cash Incentive Plan amendment: Approved with 91.4 million votes for (≈90% support) and 10.3 million against.
- Say-on-Pay frequency: A majority of 97.5 million shares favored an annual advisory vote; consequently, the company will hold future Say-on-Pay votes every year.
The filing contained no financial performance data or transactional announcements, focusing solely on corporate-governance matters. Overall, the company secured broad shareholder endorsement on all proposals, though c. 10% opposition on compensation-related items indicates a modest level of investor dissent that management may monitor going forward.